Journal
CHEMICAL COMMUNICATIONS
Volume 51, Issue 53, Pages 10624-10627Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5cc03557k
Keywords
-
Categories
Funding
- Cancer Research UK
- Engineering and Physical Sciences Research Council (EPSRC)
- BBSRC
- BRC
- Wellcome Trust
- HEFCE
- SBC
- MRC
- UCL
- UCLB
- CCIC collaboration - CRUK & EPSRC Comprehensive Cancer Imaging Centre at KCL UCL
- Biotechnology and Biological Sciences Research Council [BB/L024349/1] Funding Source: researchfish
- Cancer Research UK [21030, 16463] Funding Source: researchfish
- Medical Research Council [G1001497, MC_PC_12024] Funding Source: researchfish
- BBSRC [BB/L024349/1] Funding Source: UKRI
- MRC [G1001497, MC_PC_12024] Funding Source: UKRI
Ask authors/readers for more resources
Herein we report the use of next generation maleimides (NGMs) for the construction of a potent antibody-drug conjugate (ADC) via functional disulfide bridging. The linker has excellent stability in blood serum and the ADC, armed with monomethyl auristatin E (MMAE), shows excellent potency and cancer cell selectivity in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
